• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

AVMA counters on DEA proposal to make propofol a Schedule IV veterinary drug

December 22, 2010

The DEA proposal to make veterinary anesthetic propofol a Schedule IV drug drew caution from AVMA.

Schaumburg, Ill.

-- The Drug Enforcement Administration's (DEA) proposal to make propofol a Schedule IV drug drew a letter of caution from the American Veterinary Medical Association (AVMA).

In fact, the national association's initial response to agency was to offer "input regarding disposal" of the anesthetic agent.

"The DEA cites research that 28 percent of drug abusers of propofol die as a result of this abuse, so the AVMA understands the DEA's actions to stop diversion of propofol from its intended use," explains Dr. Ron DeHaven, chief executive officer of the AVMA in a prepared statement. "However, propofol is also an effective drug used in veterinary anesthesia, and we want to make sure that the burden of disposing of it under the DEA's rules doesn't discourage veterinarians from utilizing propofol," DeHaven says.

"The AVMA is concerned that under DEA rules, veterinarians may no longer be allowed to dispose of any unused propofol into an absorbent substance for incineration or disposal as solid waste," the association adds.

AVMA, however, did not comment on the new administrative burdens that a Schedule IV substance would require for veterinarians.

Advertisement

DEA's proposal, outlined recently in the Federal Register, would "impose regulatory controls and criminal sanctions of schedule IV on those who handle propofol and products containing propofol."

DEA's action is a result of a 2008 petition citing an increasing number of documented cases of abuse -- a trend also associated with a high mortality rate, DEA reports. In addition, the database of the Adverse Event Reporting System indicates that of all the reported diversion and abuse cases, 96 percent were committed by health-care providers.

If propofol is categorized as a schedule IV substance, veterinarians would need to seek DEA registration, maintain and keep inventory records as required by the Controlled Substances Act and impose security requirements applicable to schedules III and IV substances. Prescriptions for propofol or products containing propofol would be required, DEA says.

"The AVMA is asking the DEA to balance the essential need to protect the public from abuse of propofol while also allowing for convenient disposal of wasted propofol on an ongoing basis," DeHaven says.

At presstime, the American Veterinary Medical Association's Council on Biologic and Therapeutic Agents and its Clinicial Practitioners Advisory Committee were crafting written responses to the proposed rules.

Related Content:

MedicalAssociationBreaking News
Drug for acute onset of canine pancreatitis is launched on the US market
Drug for acute onset of canine pancreatitis is launched on the US market
New certificate program addresses the importance of self-care
New certificate program addresses the importance of self-care
Diagnostics for a thoracic trauma patient
Diagnostics for a thoracic trauma patient

Advertisement

Latest News

Drug for acute onset of canine pancreatitis is launched on the US market

New Automatic 2-in-1 Pet Feeder and Water Dispenser launched

PetHub launches AI tools for pet owners

Prairie dog pups emerge from underground at Maryland Zoo

View More Latest News
Advertisement